



## Revisiting and proposing the most important questions in cancer research and clinical oncology

Chao-Nan Qian<sup>1,\*</sup>, Francesco Pezzella<sup>2</sup>, and Zhimin Lu<sup>3</sup>

<sup>1</sup> Department of Radiation Oncology, Guangzhou Concord Cancer Center, 9 Ciji Road, Guangzhou, Guangdong 510555, China

<sup>2</sup> Nuffield Division of Clinical Laboratory Science, Radcliffe Department of Medicine, Level 4, Academic Block, John Radcliffe Hospital, University of Oxford, Headley Way, Headington, Oxford OX3 9DU, UK

<sup>3</sup> Zhejiang Provincial Key Laboratory of Pancreatic Disease, The First Affiliated Hospital, Institute of Translational Medicine, Zhejiang University School of Medicine, Zhejiang University, 268 Kai-Xuan Road, Hangzhou, Zhejiang 310029, China


Received 16 March 2024, Accepted 16 March 2024, Published online 10 April 2024

**Abstract** – Given the limitations in our understanding of cancer development and treatment options, malignant neoplasms remain a leading cause of death worldwide. In 2016, to bolster our fight against cancer, we invited authors globally to identify the most crucial questions in cancer research and clinical oncology. This effort led to the review and publication of 101 key scientific questions, sparking a surge in promising research across various domains. With the significant growth in our knowledge and evidence over the past decade, we are excited to invite authors to revisit and refine their previously published key questions. We also encourage the submission of new key questions related to malignant diseases. The deadline for submitting these impactful questions is extended to the end of 2025.

**Key words:** Cancer biology, Clinical oncology, Metastasis, Immunology, Radiotherapy.

With the dramatic development of medical sciences and technologies for cancer prevention, detection, and treatment, the incidence rates of several malignancies have declined and the cure rate for some cancers has significantly increased in certain areas of the world. However, cancer-related death is still a major cause of mortality worldwide, killing nearly 10 million patients in 2020 [1], suggesting the limitations of our understanding on carcinogenesis, cancer biology, as well as medical interventional options.

Hoping to promote basic research and clinical investigations, we launched an interesting activity in 2016 by inviting authors worldwide to present the most important questions in cancer research and clinical oncology [2]. The initial plan was to publish 150 key questions to tribute to Dr. Sun Yat-sen for his 150th year anniversary of birth, who was a physician and a pioneer in the modernization of China. By 2018, 101 most important questions have been peer-reviewed and published [3–15]. These key questions have triggered significant interest in the research fields of cancer etiology [16–19], epidemiology [20, 21], metabolism [22, 23], apoptosis [24], senescence [25], angiogenesis [26, 27], cachexia [28, 29], immunology [30–32], treatment resistance [30, 33], and novel therapeutic modality [34–37]. In Figure 1, we present the distribution of the questions categorized into broad topics, some predominantly clinical and others more biological. Interestingly, while the number of biological topics is higher, it is the clinical topics



**Figure 1. A horizontal bar chart of the previously published 101 most important questions in cancer research and clinical oncology summarized by category.** The number of questions for each category is presented. Notably, a balance between clinical and biological topics can be appreciated. With metastasis remaining the most challenging issue in cancer treatment and prevention, more key questions in this area are expected in future publications.

that contain more questions. Specifically, the groups with the most questions pertain to issues related to chemotherapy, radiotherapy, or immunotherapy.

\*Corresponding author: [chaonan.qian@ccm.cn](mailto:chaonan.qian@ccm.cn)

The rapid accumulation of multidisciplinary data and knowledge has significantly advanced our understanding of cancer biology and therapeutic approaches. Therefore, the key questions published 6–8 years ago may require revisiting and potentially revising. For instance, our limited number of questions on the tumor microenvironment (TME) (only four) underscores the need for further exploration of this critical area. The TME's profound impact on cancer progression and treatment responses necessitates a more comprehensive understanding. Additionally, a paucity of questions regarding single-cell sequencing and multi-omics data analysis suggests an opportunity for deeper investigation in these promising avenues. Formulating novel and thought-provoking questions on these topics holds immense potential to enrich our understanding of cancer.

Building upon the valuable platform of Visualized Cancer Medicine (VCM), we are excited to invite authors to revisit and refine their previously published key questions. We also warmly welcome the submission of novel key questions for peer review and potential publication in VCM. By revisiting and refining existing key questions, while also introducing novel ones, this initiative aims to reframe and revitalize cancer research, ultimately accelerating progress in the fight against this complex disease.

## References

1. Ferlay J, Ervik M, Lam F, Colombet M, Mery L, Piñeros M, et al. Global Cancer Observatory: cancer today. Lyon: International Agency for Research on Cancer; 2020. Available from: <https://gco.iarc.fr/today/home>.
2. Qian CN, Zhang W, Xu RH. Defeating cancer: the 150 most important questions in cancer research and clinical oncology. *Chin J Cancer* 2016;35(1):104.
3. Wee JT, Poh SS. The most important questions in cancer research and clinical oncology: Question 1. Could the vertical transmission of human papilloma virus (HPV) infection account for the cause, characteristics, and epidemiology of HPV-positive oropharyngeal carcinoma, non-smoking East Asian female lung adenocarcinoma, and/or East Asian triple-negative breast carcinoma? *Chin J Cancer* 2017;36(1):13.
4. Venniyoor A. The most important questions in cancer research and clinical oncology – question 2–5. Obesity-related cancers: more questions than answers. *Chin J Cancer* 2017;36(1):18.
5. Editorial Office of Chinese Journal of Cancer. The 150 most important questions in cancer research and clinical oncology series: questions 6–14: Edited by Chinese Journal of Cancer. *Chin J Cancer* 2017;36(1):33.
6. Editorial Office of Chinese Journal of Cancer. The 150 most important questions in cancer research and clinical oncology series: questions 15–24: Edited by Chinese Journal of Cancer. *Chin J Cancer* 2017;36(1):39.
7. Editorial Office of Chinese Journal of Cancer. The 150 most important questions in cancer research and clinical oncology series: questions 25–30: Edited by Chinese Journal of Cancer. *Chin J Cancer* 2017;36(1):42.
8. Editorial Office of Chinese Journal of Cancer. The 150 most important questions in cancer research and clinical oncology series: questions 31–39: Edited by Chinese Journal of Cancer. *Chin J Cancer* 2017;36(1):48.
9. Editorial Office of Chinese Journal of Cancer. The 150 most important questions in cancer research and clinical oncology series: questions 40–49. *Chin J Cancer* 2017;36(1):55.
10. Editorial Office of Chinese Journal of Cancer. The 150 most important questions in cancer research and clinical oncology series: questions 50–56. *Chin J Cancer* 2017;36(1):69.
11. Editorial Office of Chinese Journal of Cancer. The 150 most important questions in cancer research and clinical oncology series: questions 57–66: Edited by Chinese Journal of Cancer. *Chin J Cancer* 2017;36(1):79.
12. Editorial Office of Chinese Journal of Cancer. The 150 most important questions in cancer research and clinical oncology series: questions 67–75: Edited by Chinese Journal of Cancer. *Chin J Cancer* 2017;36(1):86.
13. Editorial Office of Chinese Journal of Cancer. The 150 most important questions in cancer research and clinical oncology series: questions 76–85: Edited by Chinese Journal of Cancer. *Chin J Cancer* 2017;36(1):91.
14. Editorial Office of Chinese Journal of Cancer. The 150 most important questions in cancer research and clinical oncology series: questions 86–93: Edited by Chinese Journal of Cancer. *Chin J Cancer* 2018;37(1):1.
15. Editorial Office of Cancer Communications. The 150 most important questions in cancer research and clinical oncology series: questions 94–101: Edited by Cancer Communications. *Cancer Commun (Lond)* 2018;38(1):69.
16. Fraser J. Rendering Inuit cancer “visible”: geography, pathology, and nosology in Arctic cancer research. *Sci Context* 2020;33(3):195–225.
17. Jia N, Tang Y, Li Y, Gan Y. A case report: does the ulcer belong to esophageal carcinoma or HIV? *Medicine (Baltimore)* 2017;96(49).
18. Ugare UG, Bombil I, Luvhengo TE. Early-onset malignant solid tumours in young adult South Africans – an audit based on histopathological records of patients seen at the three academic hospitals in Johannesburg. *S Afr J Surg* 2022;60(2):134–140.
19. Venniyoor A, Al Farsi AA, Al Bahrani B. The troubling link between non-alcoholic fatty liver disease (NAFLD) and extrahepatic cancers (EHC). *Cureus* 2021;13(8):e17320.
20. Xie Z, Peng W, Li Q, Cheng W, Zhao X. Ethnicity-stratified analysis of the association between XRCC3 Thr241Met polymorphism and leukemia: an updated meta-analysis. *BMC Med Genomics* 2021;14(1):229.
21. Zhu B, Wu X, Guo T, Guan N, Liu Y. Epidemiological characteristics of pancreatic cancer in China from 1990 to 2019. *Cancer Control* 2021;28:10732748211051536.
22. Wang YX, Zhu N, Zhang CJ, Wang YK, Wu HT, Li Q, et al. Friend or foe: multiple roles of adipose tissue in cancer formation and progression. *J Cell Physiol* 2019;234(12):21436–21449.
23. Wei XT, Feng GJ, Zhang H, Xu Q, Ni JJ, Zhao M, et al. Pleiotropic genomic variants at 17q21.31 associated with bone mineral density and body fat mass: a bivariate genome-wide association analysis. *Eur J Hum Genet* 2021;29(4):553–563.
24. Sakane F, Hoshino F, Ebina M, Sakai H, Takahashi D. The roles of diacylglycerol kinase alpha in cancer cell proliferation and apoptosis. *Cancers (Basel)* 2021;13(20):5190.
25. Wu J, Su HK, Yu ZH, Xi SY, Guo CC, Hu ZY, et al. Skp2 modulates proliferation, senescence and tumorigenesis of glioma. *Cancer Cell Int* 2020;20:71.
26. Binisor I, Banita IM, Alexandru D, Mehedinti MC, Jurja S, Andrei AM, et al. Progranulin: a proangiogenic factor in visceral adipose tissue in tumoral and non-tumoral visceral pathology. *Exp Ther Med* 2021;22(5): 1337.
27. Qian CN, Pezzella F. Tumor vasculature: a sally port for inhibiting cancer cell spreading. *Cancer Commun (Lond)* 2018;38(1):52.
28. Comiran PK, Ribeiro MC, Silva JHG, Martins KO, Santos IA, Chiaradia AEF, et al. Botryosphaeran attenuates tumor development and the cancer cachexia syndrome in walker-256 tumor-bearing obese rats and improves the metabolic and hematological profiles of these rats. *Nutr Cancer* 2021;73(7):1175–1192.
29. Ejder ZB, Sanlier N. The relationship between loneliness, psychological resilience, quality of life and taste change in cancer patients receiving chemotherapy. *Support Care Cancer* 2023;31(12):683.
30. Fu L, Li S, Xiao W, Yu K, Li S, Yuan S, et al. DGKA mediates resistance to PD-1 blockade. *Cancer Immunol Res* 2021;9(4): 371–385.
31. Hristova MG. Neuroendocrine and immune disequilibrium as a probable link between metabolic syndrome and carcinogenesis. *Med Hypotheses* 2018;118:1–5.
32. Hu W. Multiplex immunohistochemistry/immunofluorescence is superior to tumor mutational burden and PD-L1 immunohistochemistry for predicting response to anti-PD-1/PD-L1 immunotherapy. *Thorac Cancer* 2020;11(1):3–5.
33. Mirzayans R, Murray D. Intratumor heterogeneity and therapy resistance: contributions of dormancy, apoptosis reversal (anastasis) and cell fusion to disease recurrence. *Int J Mol Sci* 2020;21(4):1308.
34. Dong L, Neuzil J. Targeting mitochondria as an anticancer strategy. *Cancer Commun (Lond)* 2019;39(1):63.

35. Ogino S, Nowak JA, Hamada T, Phipps AI, Peters U, Milner DA Jr, et al. Integrative analysis of exogenous, endogenous, tumour and immune factors for precision medicine. *Gut* 2018;67(6):1168–1180.
36. Seeruttun SR. Equibalancing immune-related adverse events and anticancer activity of immune checkpoint inhibitors. *Thorac Cancer* 2019;10(10):1855–1856.
37. Zhang MX, Liu T, You R, Zou X, Liu YL, Ding X, et al. Efficacy of local therapy to metastatic foci in nasopharyngeal carcinoma: large-cohort strictly-matched retrospective study. *Ther Adv Med Oncol* 2022;14:17588359221112486.

**Cite this article as:** Qian C-N, Pezzella F, Lu Z. Revisiting and proposing the most important questions in cancer research and clinical oncology. *Visualized Cancer Medicine*. 2024; 5, E1.